<DOC>
	<DOCNO>NCT00004804</DOCNO>
	<brief_summary>OBJECTIVES : I . Determine whether initial response interferon alfa ( IFN-A ) increase start dose 5 MU three time week patient chronic hepatitis C. II . Determine whether patient normalized alanine aminotransferase ( ALT ) level maintain normal ALT stepwise dose reduction 5 MU 3 MU 1.5 MU .</brief_summary>
	<brief_title>Phase III Randomized Study High Vs Standard Dose Interferon Alfa Chronic Hepatitis C</brief_title>
	<detailed_description>PROTOCOL OUTLINE : Patients randomly assign 1 2 treatment group 2:1 ratio . The first group treat high-dose interferon alfa ( IFN-A ) administer subcutaneously twice week 12 week . If alanine aminotransferase ( ALT ) level normalize , IFN-A dose decrease stepwise fashion . If ALT level decrease 50 % , IFN-A continue dose week 24 ALT normalizes . If ALT level decrease less 50 % , treatment discontinue . The second group treat standard-dose IFN-A administer subcutaneously twice week 24 week .</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<criteria>PROTOCOL ENTRY CRITERIA : Disease Characteristics Biopsyproven chronic hepatitis Antihepatitis C virus positive Hepatitis B surface antigen negative No decompensated cirrhosis Prior/Concurrent Therapy No concurrent immunosuppressive At least 1 year since interferon Patient Characteristics Hepatic : No cause liver disease Other : Not HIV positive</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 1997</verification_date>
	<keyword>hepatitis C</keyword>
	<keyword>immunologic disorder infectious disorder</keyword>
	<keyword>rare disease</keyword>
	<keyword>viral infection</keyword>
</DOC>